Francois-Xavier Bicharh Otte

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
677 Background: A 2004 randomized study showed a meaningful improvement in survival with bev added to chemotherapy (CT) for patients with mCRC. This combination is now widely used and generally well tolerated although adverse events (AEs) are described associated with the use of bev, some of which may be increased in incidence in an elderly population. In(More)
Most patients with recurrent and metastatic rectal cancer cannot be cured. Selected patients with local recurrence or liver and/or lung-limited metastatic disease are sometimes curable with radiation therapy (RT) or surgery. However, for the majority of patients, treatment is palliative and systemic therapy remains the mainstay treatment. Over the last ten(More)
  • 1